Most Read Articles
Roshini Claire Anthony, 4 days ago

Individuals with moderate-to-severe plaque psoriasis may reap better long-term improvements in the severity of their condition when treated with guselkumab over secukinumab, according to findings of the phase III ECLIPSE* trial presented at the recent Inflammatory Skin Disease Summit (ISDS 2018) held in Vienna, Austria.

Jairia Dela Cruz, 11 Jan 2019
Use of standard-dose aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) appears to confer protection against the risk of endometrial cancer in overweight and obese women, according to a meta-analysis.
Elvira Manzano, 5 days ago
Treatment with two investigational, oral JAK inhibitors may be beneficial in individuals with moderate‐to‐severe alopecia areata (spot baldness), an autoimmune disease that can cause a lot of anxiety, according to an ongoing phase II study.
3 days ago
Discontinuing the use of tyrosine kinase inhibitors (TKIs) in the treatment of patients with chronic myeloid leukaemia appears to be feasible in real-life clinical practice in the context of close molecular monitoring, a study reports.

Extremely premature birth negatively influences visual outcomes in early adult life

15 Sep 2018

Young adults born extremely preterm (EP) exhibit considerable structural alterations at the fovea, a study has shown. Increased ganglion cell layer thickness is associated with poor best-corrected visual acuity (BVCA), with retinal layer thickness and BCVA being profoundly affected in eyes requiring neonatal treatment for retinopathy of prematurity (ROP).

Researchers followed 177 young adults (354 eyes; 226 from former EP infants and 128 from age-matched full-term controls) for 19 years to quantify inner and outer retinal layer thicknesses in relation to visual function.

In the EP group, 50 percent of eyes were not previously diagnosed with neonatal ROP, 38 percent had ROP not requiring treatment in the neonatal period, and 13 percent had neonatal cryotherapy or laser ablation for ROP.

Compared with control eyes, EP eyes showed significantly thicker inner and outer retinal layers and reduced BCVA. Retinal layer thicknesses and BCVA did not differ between eyes with untreated ROP and those without neonatal ROP. On the other hand, eyes with treated ROP had greater inner and outer retinal layer thickness and decreased vision.

Worse BCVA correlated with inner retinal layer thickness (p<0.001) but not outer retinal layer thickness (p=0.80). In multivariate linear regression models, ganglion cell layer thickness was a significant independent predictor of BCVA.

The present data provide insight into the pathophysiologic mechanisms after preterm birth that are involved in the maturation of the human fovea, researchers said.

Longitudinal studies are needed to examine changes in the retinal layers and visual acuity over time, as well as determine the postnatal age at which the increase in retinal ganglion layer thickness stops. This information would be important for future clinical trials using age-specific retinal thickness profiles as endpoints to predict visual acuity changes in ROP.

Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 4 days ago

Individuals with moderate-to-severe plaque psoriasis may reap better long-term improvements in the severity of their condition when treated with guselkumab over secukinumab, according to findings of the phase III ECLIPSE* trial presented at the recent Inflammatory Skin Disease Summit (ISDS 2018) held in Vienna, Austria.

Jairia Dela Cruz, 11 Jan 2019
Use of standard-dose aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) appears to confer protection against the risk of endometrial cancer in overweight and obese women, according to a meta-analysis.
Elvira Manzano, 5 days ago
Treatment with two investigational, oral JAK inhibitors may be beneficial in individuals with moderate‐to‐severe alopecia areata (spot baldness), an autoimmune disease that can cause a lot of anxiety, according to an ongoing phase II study.
3 days ago
Discontinuing the use of tyrosine kinase inhibitors (TKIs) in the treatment of patients with chronic myeloid leukaemia appears to be feasible in real-life clinical practice in the context of close molecular monitoring, a study reports.